Compare Citius Pharmaceuticals Inc (CTXR) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Deckers Outdoor Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Deckers Outdoor Corp trades at $82.89 (market cap $11.24B). The key difference: Deckers Outdoor Corp is far larger — about 825.3× Citius Pharmaceuticals Inc's market cap, and Deckers Outdoor Corp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Deckers Outdoor Corp for 71 Days on average.
| CTXR | DECK | |
|---|---|---|
Market Cap | $13.62M | $11.24B |
Volume | 132,438 | 3,010,945 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $120.94 |
52-Week Low | $0.48 | $77.51 |
Typical Hold Time | 17 Days | 71 Days |
Enterprise Value | $3.79M | $10.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
DECK trades at $82.56, up 2.71% today, with a bullish technical signal and strong fundamentals. Recent earnings beats and robust brand momentum from HOKA and UGG support growth. The stock shows high profitability with a net margin of 18.36% and ROE of 42.56%. Valuation ratios like P/E of 11.74 appear attractive relative to earnings power. Support is firm near $81, with resistance at $83.
Outlook remains positive given consistent earnings outperformance and analyst consensus price target of $117.13, implying significant upside. Risks include reliance on key brands and competitive pressures. Institutional interest is strong, but investors should monitor execution on fiscal 2027 growth targets amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
